Since January 2020 Elsevier has created a COVID-19 resource centre with free information in English and Mandarin on the novel coronavirus COVID-19. The COVID-19 resource centre is hosted on Elsevier Connect, the company's public news and information website.

Elsevier hereby grants permission to make all its COVID-19-related research that is available on the COVID-19 resource centre - including this research content - immediately available in PubMed Central and other publicly funded repositories, such as the WHO COVID database with rights for unrestricted research re-use and analyses in any form or by any means with acknowledgement of the original source. These permissions are granted for free by Elsevier for as long as the COVID-19 resource centre remains active.
Cycle threshold values from SARS-CoV-2 PCR assays: Interpretation and potential use cases

Alexander J. McAdam, M.D., Ph.D

PII: S0272-2712(22)00014-2
DOI: https://doi.org/10.1016/j.cll.2022.02.003
Reference: CLL 1169

To appear in: CLINICS IN LABORATORY MEDICINE

Please cite this article as: McAdam AJ, Cycle threshold values from SARS-CoV-2 PCR assays: Interpretation and potential use cases, CLINICS IN LABORATORY MEDICINE (2022), doi: https://doi.org/10.1016/j.cll.2022.02.003.

This is a PDF file of an article that has undergone enhancements after acceptance, such as the addition of a cover page and metadata, and formatting for readability, but it is not yet the definitive version of record. This version will undergo additional copyediting, typesetting and review before it is published in its final form, but we are providing this version to give early visibility of the article. Please note that, during the production process, errors may be discovered which could affect the content, and all legal disclaimers that apply to the journal pertain.

© 2022 Elsevier Inc. All rights reserved.
Cycle threshold values from SARS-CoV-2 PCR assays: Interpretation and potential use cases

Alexander J. McAdam, M.D., Ph.D. Medical Director, Infectious Diseases Diagnostic Laboratory, Boston Children’s Hospital and Associate Professor of Pathology at Harvard Medical School

Mailing Address: Department of Laboratory Medicine, Boston Children’s Hospital, 300 Longwood Avenue, Boston, MA 02115

Email Address: alexander.mcadam@childrens.harvard.edu

Twitter: @JClinMicro

Corresponding Author: Alexander J. McAdam

Disclosure Statement: The author has nothing to disclose

Key Words: COVID-19, SARS-CoV-2, Reverse transcription polymerase chain reaction, Cycle threshold value

Key Points

- The cycle threshold (Ct) value is a semi-quantitative value that is inversely related to the level of viral RNA in reverse-transcription polymerase chain reaction (RT-PCR) tests for severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2)
- The Ct value for SARS-CoV-2 is inherently variable due to the variability of RT-PCR, and further variability can be introduced by sample factors (collection, storage, sample type), and use of different RT-PCR tests.
- Potential clinical uses of Ct values for SARS-CoV-2 include assessment of the progression of infection, prediction of disease severity and determination of infectivity.
Caregivers using Ct values for these purposes must understand the variability and limitations of Ct values, which can be facilitated by direct communication with the leadership of the clinical laboratory.

Synopsis

Reverse-transcription polymerase chain reaction (RT-PCR) tests for severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2), the cause of coronavirus disease 2019 (COVID-19), are approved for qualitative use. The cycle threshold (Ct) value reflects the concentration of viral RNA in the sample, with lower Ct values indicating higher levels of RNA. Caregivers may wish to use the Ct value to determine progression of infection, how severe the infection will be and whether the patient can transmit the virus. Variability of Ct values and the data supporting these uses should be considered when deciding whether and how to use Ct values in clinical care.
Introduction

The coronavirus disease 2019 (COVID-19) pandemic, caused by the severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2) has caused over 381 million infections and over 5.6 million deaths, worldwide, including over 75 million infections and over 890,000 deaths in the United States. While use of vaccines has slowed the mortality rates in many places, lack of access to vaccines and vaccine hesitancy have resulted in continued infections and deaths. Diagnostic testing for SARS-CoV-2 has been and will continue to be critical to addressing the pandemic.

The mainstay of diagnostic testing is nucleic acid amplified tests, primarily using reverse transcription followed by polymerase chain reaction (RT-PCR). RT-PCR tests for SARS-CoV-2 are designed and validated to be used as qualitative tests, reporting as positive if the virus is detected or negative if it is not. RT-PCR can be made quantitative if a standard curve is generated using known concentrations of virus or viral RNA, allowing use of the sample cycle threshold (Ct) at which viral RNA is detected to estimate the quantity of virus present. Alternatively, the Ct value alone can be used directly, as a semi-quantitative way to compare the level of virus between two samples run using the same assay on the same platform.

While PCR and RT-PCR have been used to detect viral pathogens for several years, is it only during the COVID-19 pandemic that there has been serious consideration of using Ct values for clinical care and infection control measures. This has been an area of active debate. Professional organizations, including the Association for Molecular Pathology, Infectious Diseases Society of America, the Association of Public Health Laboratories and the American Association of Clinical Chemistry have issued guidelines against using Ct values for clinical care. Regardless of this, laboratory directors are frequently asked to supply Ct values for various purposes, discussed below, and need to be prepared for such requests.
Furthermore, in at least one state in the U.S., Florida, clinical laboratories are required to report Ct values to the state Department of Public Health, but not in clinical reports to care providers. 

Before turning to a discussion of the potential uses of Ct values, it is important to understand the regulatory status of reporting Ct values for SARS-CoV-2. Because RT-PCRs for SARS-CoV-2 have been approved for use as qualitative assays, reporting a quantitative result, such as a Ct value, is a regulatory violation. Reporting these values to providers outside of the laboratory report does not necessarily prevent them from appearing in the medical record, as they can be included in the clinical notes. Laboratory directors should understand the potential consequences of reporting Ct values and consider this in determining how and whether to provide these values for clinical care.

The remainder of this review will include three topics. First, the variability of Ct values for SARS-CoV-2 will be briefly discussed, as this is important to understanding the potential utility of these values. Second, the evidence for and against various uses of Ct values will be reviewed. Finally, specific recommendations will be made for those who have decided to provide Ct values to clinical caregivers or for infection control purposes.

**Variability of Ct Values**

It is important to understand the sources and magnitude of variability of Ct values for SARS-CoV-2. This variability can be reduced or minimized, but it cannot be eliminated (table 1). Clinical staff should understand that Ct values can be highly variable and this is one of several reasons why these values must be interpreted with caution. Information about the variability of Ct values can be provided within the laboratory report or during consultation between the laboratory director and clinical staff, prior to release of Ct values. These data should not be provided without a complete explanation of the expected variability and of what changes might be considered meaningful in the context of clinical care.
There are several sources of variability in Ct values, and these are discussed separately in the sections that follow. In considering these sources of variability, several things should be kept in mind. First, the methods used in these studies vary significantly. For brevity, the most important differences in methods will be discussed, but less important differences will not. Second, these papers often show summary data, such as means and standard deviations, graphically, but they may not provide the numerical values. In such cases, differences between Ct values have been estimated by inspection of the figures. Third, these papers often include separate analysis of the targets of amplification for those assays that include more than one target. For the most part, the different targets within a specific assay do not vary much in their Ct values, and so this level of detail will not be discussed except where necessary.

**Variability associated with SARS-CoV-2 RT-PCR Tests**

Different RT-PCR tests for SARS-CoV-2 can yield very different Ct values. This is to be expected, given that the assays amplify different regions of the viral genome using different primers and probes and include different reagents, all of which will contribute to variations in the efficiency of the RT-PCR between assays. Reasonably comprehensive data on this issue were provided by the College of American Pathologists (CAP) Microbiology Committee in response to a paper in *Clinical Infectious Diseases*. These data were collected from participants using CAP proficiency test materials. The median Ct values between different tests varied by as much as 14 cycles. Even within a single gene target on a single assay, between-laboratory results varied by up to 12 cycles. Papers in which various assays were validate or compared have similarly found differences in Ct values that ranged from 5 to slightly more than 14 cycles. Importantly, because of high test volumes and the need for reasonable turn-around-time, many laboratories have had to run several different assays. Potentially large differences in the Ct
values between assays must be considered if values are compared between assays performed in different or the same laboratory.

Variability Associated with Transport Medium and Sample Storage

The effect of dilution and storage of SARS-CoV-2 in different media, including M4, minimal essential media (MEM), phosphate buffered saline, 0.9% saline, as well as in patient samples (sputum and bronchoalveolar lavage) has been evaluated. Briefly, two studies, each which included several prospective transport media or sample types, demonstrated that there was no increase greater than two in the Ct values for any media or sample type following storage at temperatures ranging from room temperature to -10 to -30°C during seven days of storage.\(^9,10\) Ct increases of slightly more than 2 were seen after storage of samples in saline after 14 days at refrigerator or freezer temperatures. In a third study, storage of SARS-CoV-2 in phosphate buffered saline at room temperature, 4°C, -20°C and -80°C had little effect on the Ct at 7 days.\(^11\) From 14 to 28 days, samples with a lower level of virus (500-1,000 copies/mL) had increased Ct values of slightly more than two, and some samples became negative at room temperature, 4°C, and -20°C but not at -80°C. Samples with a higher level of virus (5,000 to 10,000 copies/mL) did not show significant changes in the Ct values at any of these temperatures. In summary, storage at room temperature or 4°C for up to a week has minimal effect on the Ct values for SARS-CoV-2, but if samples are stored longer there may be small increases of 2-3 Ct and lower levels of virus may become undetectable.

Variability Associated with Sample Type

There are sizable differences in the Ct values of different types of respiratory samples. Several studies compare the Ct values between different specimens of the upper respiratory tract. Saliva will be included here, because it presumably represents a mixture of saliva and mucosal upper respiratory tract
secretions, with the latter presumably containing SARS-CoV-2 RNA. Because there is so much variation in the methods of sample collection and processing, the findings are generally specific to the institution where the study was conducted, so only a few general points can be made. First, nasopharyngeal samples usually have Ct values lower than or equal to other sample types studied. Compared to nasopharyngeal samples, nasal swabs, saliva, and oral swabs have values that are approximately 5 to 7 cycles higher in some studies. Other studies have found similar Ct values for nasopharyngeal and nasal swabs, or for nasopharyngeal swabs, throat swabs, sputum and dual throat/nasopharyngeal samples. A small study found that Ct values of tracheal aspirates were on average 3 cycles higher than those of nasopharyngeal swabs. When the Ct values were normalized to the human RNaseP gene that was included in the assay, there was no difference between the values from tracheal aspirate and nasopharyngeal swab specimens, however the meaning of standardizing Ct values of viral RNA to human RNA is not clear.

At the time of writing, there were no studies that compared Ct values for SARS-CoV-2 PCR between samples from the upper respiratory tract and the lower respiratory tract. There are case reports and case series that show that qualitative results of bronchoalveolar lavage samples differ from those of NP swabs or other upper respiratory samples. These reports usually emphasize the importance of testing lower respiratory samples to optimize detection of SARS-CoV-2. Given these discrepant results, and the sample dilution required to collect a bronchoalveolar lavage sample, it is inevitable that there will be differences between Ct values of upper and lower respiratory samples. It is unlikely that the sample matrix will greatly affect the Ct values, at least if the method of RNA purification is adequate and consistent. It is strongly recommended that the same sample type and assay be used to compare Ct values within a patient over time, unless there is sufficient local data to allow providers to make informed comparisons.
Possible use cases for Ct values for SARS-CoV-2

There are three potential uses of Ct values that are adequately discussed in the literature to merit review. These include, first, possible use of Ct values to evaluate the progression or course of COVID-19, second, the prognostic use of Ct values as predictors of clinical severity of infection and, third, use of Ct values to determine whether a patient is potentially infectious.

Use of Ct values to determine progression of infection

Caregivers may want to use the Ct value or multiple Ct values to determine whether the viral load is rising or falling, as a marker of whether the patient is recovering from infection. A similar, but perhaps less common use, is to use the Ct to try to determine approximately how long the patient has been infected. The utility of the Ct value for these applications depends on several things, including the average kinetics of the viral load (and associated Ct) in affected persons, the variability of these kinetics within an individual patient, and how the kinetics differ in patients who are immunocompromised. Each of these will be discussed.

A study early in the pandemic provided pooled and individual-patient data on the Ct values of patients with acute COVID-19. 18 While the number of patients is small at 14, the study is valuable because the trends over time after the onset of symptoms are shown for individual patients. Nasal (mid-turbinate and nasopharyngeal) swabs or throat swabs were analyzed separately, using RT-PCR which detected regions of the N and ORF1b genes. Ct values for ORF1b were tracked over time for each patient. From this study, it is clear that aggregated Ct values are lower in the first week after symptom onset, and then higher thereafter for both specimen types, with nearly all patients having negative results by 21 days after symptom onset. However, there is marked variability in Ct values between and within patients. From inspection of the graphs, for each of the two specimen types, at least five patients had samples
that were negative followed by samples that were positive for SARS-CoV-2. Furthermore, although the aggregate Ct values rose over time, indicating falling levels of viral RNA, several patients had decreases in the Ct values of greater than eight to ten, followed by rising Ct values or negative results. Taken together, these results indicate that results within an individual patient can be highly variable, and so using a small number of Ct values to track a patient's course may be misleading.

Numerous case reports and case series show that people who are immunocompromised can have prolonged infection with SARS-CoV-2. The largest of these includes 20 patients receiving immunosuppressive therapies for various cancers. Unfortunately, the publication does not include Ct values, however RT-PCR results are summarized and detection of replication-competent virus is presented in some detail. Viral RNA could be detected as late as 78 days after onset of symptoms (interquartile range, 24 to 64 days). Three of 20 patients shed replication competent virus for more than 20 days. A smaller series, including only 3 patients with various causes of immunosuppression and prolonged infection with SARS-CoV-2, includes Ct values. Again, as has been discussed above, there is marked variation in the Ct values over time, with apparent reductions in viral RNA being followed by increases, so that one could be misled by trying to track the course of infection by using these values.

Perhaps the longest documented shedding of replication competent SARS-CoV-2 was 238 days in an immunocompromised patient was seen in a patient with mantle cell lymphoma receiving treatment with rituximab, bendamustine and cytarabine.

**Use of Ct Values to Predict Severity of COVID-19**

The prognostic utility of the Ct value at or shortly after patient admission was assessed in a retrospective study performed at two hospitals in New York City. Hospitalized patients testing positive for SARS-CoV-2 by RT-PCR using nasopharyngeal swab specimens collected within a day of
admission were included. RT-PCR was performed using an assay which detects regions of the E gene and the ORF1ab gene, and Ct values from the ORF1ab gene were used to divide the patients into three roughly equally sized groups, with Ct values of <25 (high viral load), 25-30 (medium viral load) and >30 (low viral load). Patients whose samples were positive for the E gene but negative for the ORF1ab gene were included in the low viral load group. A total of 678 patients were studied. There was a strong relationship between the viral load and in-hospital mortality, with mortality rates of 35%, 17.6% and 6.2% for the high, medium and low viral load groups respectively. The proportion of patients who were intubated similarly related to viral load, with 29.1%, 20.8% and 14.9% for the three groups. Finally, multivariate analysis which included multiple risk factors such as age, race and several comorbidities revealed a significantly increased risk of mortality in the high viral load group compared with the low viral load group, with an odds ratio of 6.05 (95% confidence interval 2.92-12.52).

Another approach has been to evaluate the prognostic value of a rising or falling Ct value over time. This was investigated in a retrospective study at a single institution. Patients who presented to the Emergency Department with radiological and clinical evidence of pneumonia who had two or more positive SARS-CoV-2 RT-PCRs with the same assay more than 24 hours apart were included. RT-PCR was performed using an assay that amplifies the N2 and E genes, and the Ct values for the N2 results were analyzed. Clinical status was determined using the sequential organ failure assessment (SOFA) score, which includes scores for six organ systems and predicts clinical outcomes in critically ill patients. Only 42 patients met the inclusion criteria, which is not surprising since there was no systematic re-testing required. The number of tests performed and time between tests varied, as these depended on the needs of clinical care. With these caveats, there was a relationship between the change in Ct value and the change in the SOFA score. Overall, an increase of 1 Ct value, indicating a reduction in the viral load, was associated with a decrease in the SOFA score of 0.05, indicating clinical improvement. It should be noted that many of the repeat tests were performed in patients as part of discharge planning, and this
may have biased the patients studied to include those with clinical improvement. This results of this small study indicate that further research into the relationship between changes in Ct scores and changes in clinical outcomes is warranted.

A number of small studies have been done to evaluate the utility of the Ct value or viral load for predicting severity of illness. The Ct value of saliva was retrospectively evaluated, using a non-standardized clinical score, and lower Ct values were found in patients with more severe manifestations of COVID-19. One study did not find a strong relationship between the Ct value and clinical outcome in 875 patients with COVID-19. Patients with SARS-CoV-2 detected by RT-PCR for regions of the N1 and N2 genes were classified as having mild (no hospital admission), moderate (hospitalized in non-intensive care units) or severe (admitted to the intensive care unit) disease. The Ct values of those with moderate disease were slightly higher, on average, than those with mild or severe disease, but there was significant overlap in the Ct distribution of the three groups.

Taken together, these studies indicate that patients with more severe COVID-19 tend to have lower Ct values early in the course of illness or at the time they present for medical care. However, the utility of the Ct value is limited as values overlap between groups classified by disease severity such that the values are unlikely to be useful for the care of individual patients. Furthermore, there are no data supporting the use of Ct values in making therapeutic decisions. Instead, decisions about therapy are generally guided by the clinical severity of disease.

**Use of Ct values to determine infectivity**

A number of studies have assessed whether lower Ct values can be used to predict who is more likely to transmit SARS-CoV-2. There have been two approaches to this question. Initial studies looked at the relationship between Ct values and viral culture as a proxy for infectivity. These studies required
containment at BL-4 or, more recently, BL-3, and facilities for viral culture, so they could only be performed at a limited number of sites. It is important to bear in mind that the accuracy of viral culture as a surrogate for infectivity of human contacts with an index case is not known, and it is possible that viral culture overestimates or underestimates infectivity of an index case for contacts. The second, more recent approach is to link Ct values determined in routine laboratory testing to transmission events detected in epidemiologic programs meant to reduce transmission. This approach is clearly more powerful than the use of viral culture, but it also has limitations. Specifically, it cannot be definitively determined whether those contacts who become infected after exposure to an index case acquired their infection through that contact or through another contact. This could be evaluated by typing the virus, for example with viral genome sequencing, however such a study has not been done.

One of the earliest studies to evaluate the relationship between Ct values and viral culture results included 183 nasopharyngeal and sputum samples that were positive by RT-PCR for the E gene of SARS-CoV-2. Samples were stored at 4°C for up to 10 hours before being processed for viral culture. Culture was performed with Vero cells, with blind subculture twice for those viral cultures not demonstrating cytopathic effect. All samples with Ct values below 17 had growth of SARS-CoV-2 in culture, while none with Ct values greater than 34 did. No samples collected greater than 8 days after the onset of symptoms had growth of the virus in culture. A subsequent study by the same investigators expanded these data to include 3,790 samples, selected and processed as above, and demonstrated that samples with higher Ct values were less likely to contain SARS-CoV-2 detectable by culture. However, 3% of samples with a Ct value of 35 contained detectable virus in culture. No samples with Ct values greater than 35 had positive viral cultures for SARS-CoV-2.

A separate study by Bullard et al found similar results, but with some important differences. This study used 90 nasopharyngeal or endotracheal samples that were positive for SARS-CoV-2 using an RT-PCR assay targeting the E-gene. The samples were in viral transport medium and they were stored at 4°C
for 2-3 days and then frozen at -80°C for 2 to 4 weeks. Viral culture with serial dilution of the sample was performed using Vero cells. The authors showed that virus could be detected by culture as long as 8 days after the onset of symptoms and that samples positive by culture had mean Ct values of 17, compared to those that were negative by culture, which had mean Ct values of 27. All samples with virus that was detectable by culture had Ct values below 24. An excellent editorial commentary which accompanied this paper pointed out that the Ct value above which no samples are positive by viral culture varies between studies, and that the effect of storing the samples on the sensitivity of viral culture is unknown. 29

A different group evaluated the relationship between the Ct value and viral culture using 234 samples of several types, 97% of which were from the upper respiratory tract. 30 RT-PCR was performed using five primer-probe sets (E, RdRp, N, M and ORF1ab) for patients in the intensive care unit and various subsets of these for other patients. Viral culture was performed using Vero cells, with terminal RT-PCR for cultures which did not show cytopathic effect. Unlike the studies discussed above, this study found a small number of samples positive in viral culture from patients with symptom onset at 17 and 18 days. For the N gene, the mean Ct value for samples with SARS-CoV-2 detectable by cytopathic effect was 25.0, while samples without cytopathic effect or terminal RT-PCR positivity had a mean Ct value of 36.9. The highest N gene Ct value for which virus could be detected in viral culture was 32. Although numerical values are not provided for the other primer-probe sets, there were much smaller differences than those for the N gene, with the exception of the ORF1ab primer-probe set. Finally, a study which used quantitative RT-PCR to measure the number of copies of viral RNA / mL found results similar to those in the studies already discussed, confirming that the Ct value is a reasonable surrogate for the burden of replication-competent virus. 31

Taken together, these studies show that the Ct values used to predict infectivity in viral culture vary greatly, with the relevant values ranging from 24 to 35. Thus, using a specific Ct value to predict whether
viral culture will be positive would have to be informed by local data. However, culture of SARS-CoV-2
requires a biosafety level 3 laboratory according to the CDC recommendations \textsuperscript{32}, and similar practices
are recommended by the World Health Organization. \textsuperscript{33} Many laboratories lack BSL-3 facilities, and
those that have such facilities may not perform viral culture within them. Therefore in practice,
collecting such data is impractical at most institutions.

Two recent studies evaluated the relationship between Ct values for SARS-CoV-2 and transmission of
infection using RT-PCR results and information from contact tracing to track transmission of infection.
The smaller of the studies was done at Tulane University, in New Orleans, LA. \textsuperscript{34} It included college
students under 23 years of age. Students were tested twice weekly for a two-month period, using
nasopharyngeal swab specimens that were tested within 24 hours of sample collection. The RT-PCR
assay had primer-probe sets to amplify regions of the N, S and ORF1ab genes. The Ct values for the
three were averaged for data analysis. A total of 61,982 tests were performed on 7,440 students, 602 of
whom had at least one positive result. Of these, 195 were identified as index cases with one or more
close contacts; 94 spread the infection to one or more close contacts and 101 did not. The surprising
result was that the mean Ct value for those who spread infection was essentially the same as for those
who did not (23.99 and 24.02 respectively), with very similar distributions of the Ct values. The median
Ct values differed slightly, at 22.47 for those who spread infection and 24.43 for those who did not. The
authors conclude that it is not practically feasible to predict who will spread infection using the Ct values
as determined by the methods used.

The second study came to different conclusions, finding a strong correlation between lower Ct values in
index cases and risk of transmission. \textsuperscript{35} Data were collected from three high-throughput testing centers
performing community testing over a six-month period in England with linked contact tracing. The test,
performed using combined nose and throat swabs, included detection of regions of the S, N and ORF1ab
genes. Lack of amplification of the S gene was used as a surrogate for detection of the alpha or B.1.1.7
variant of SARS-CoV-2. This large study included 1,064,004 index cases with 2,474,065 contacts, 231,498 of whom had positive RT-PCR for SARS-CoV-2. Different types of contact (household, household visitor, events/activities, work/education and outdoors) were considered separately, and are listed in descending order of the risk of transmission. For each category of contact, there was a roughly linear relationship between the Ct value and the proportion of contacts with SARS-CoV-2 detected within 1 to 10 days following contact after initial diagnosis of the index case. Among household contacts, for example, rates of positive SARS-CoV-2 PCR positivity were 11.7% when the index case had a Ct value of 15, and 4.5% when the index case had a Ct value of 30. Failure of S gene amplification, indicating the likely presence of the alpha variant of SARS-CoV-2, increased the risk of transmission by 1.44 to 1.55 fold, depending on the Ct value of the sample. The strengths of this study are the large size and the careful analysis by contact type and SARS-CoV-2 variant, which make the results more robust than the previous study and highly generalizable. Similar results were found in a study of the risk of transmission from individuals with different viral loads (not Ct values) in respiratory samples: the secondary attack rate was 12% for index cases with $10^6$ or fewer copies of RNA per mL, but 24% for index cases with $10^{10}$ or greater. 36

**Recommendations on reporting Ct values**

The decisions of whether and when to report Ct values should be made by the laboratory directors in consultation with local experts in compliance and departmental leadership. If the leadership group decides that Ct values should be reported, several other decisions should be made before proceeding. The first task is to decide whether all results will be reported or if they will be selectively reported, i.e. upon request. Reporting of all results may cause confusion among caregivers who do not know how to interpret the information, therefore selective reporting would seem to be the better choice. Second, if reporting is to be done selectively, it must be determined who may request the information. One option would be to work with the infectious diseases practitioners at the institution and provide them with the
information needed to understand and utilize these results. If caregivers from other specialties request Ct values, they could be directed to involve infectious diseases specialists so that the information is used appropriately. The third task involves providing the supporting information necessary to help providers correctly interpret a Ct value. Basic information to be provided includes the fact that lower Ct values indicate higher concentrations of viral RNA and that a difference of 3 Ct values indicates approximately a 10-fold different level of viral RNA. Local data about RT-PCR efficiency might be used to provide a more precise relationship between these values. An understanding of the factors underlying the variability of Ct values is essential, so that simple mistakes, such as comparing Ct values from different specimen types, are avoided. Finally, basic statistical values of the Ct values obtained in the laboratory should be used to understand the Ct value. These could include, for example, the mean, median and interquartile ranges for symptomatic patients results.

**Clinics Care Points**
| Source of Variability          | Magnitude of Variation | Mitigation Strategies                                      |
|-------------------------------|------------------------|------------------------------------------------------------|
| Use of different RT-PCR       | Small to large         | Use the same assay, performed in the same laboratory if values will be compared between different samples |
| Assays                        |                        |                                                             |
| Transport Media               | Small                  | Not needed                                                  |
| Sample Storage                | Small if samples are less than a week old at temperatures from room temperature to -80°C | If sample retention is longer than a week, freeze samples, preferably at -80°C |
|                              | Moderate if samples are held longer than a week at room temperature or 4°C (low-levels of RNA may become undetectable) |                                                             |
| Sample type                   | Small to moderate, with nasopharyngeal swabs generally having lower Ct values than other samples from the upper respiratory tract | Use the same type of sample if values are compared between samples |
|                              |                        | Nasopharyngeal swab samples may be preferred if Ct values are compared |
Table 1. Sources of Variability in RT-PCR for SARS-CoV-2. Variations in Ct values are designated as small if they are 2 or smaller, moderate if they are greater than 2 but smaller than 7, and large if they are 7 or greater.
References

1. Center for Systems Science and Engineering (CSSE) at Johns Hopkins University (JHU). COVID-19 Dashboard. Available at https://coronavirus.jhu.edu/map.html. Accessed February 2, 2022.

2. Important Issues to Consider Before Interpreting and Applying Ct Values in Clinical Practice. July 14, 2021. Accessed July 14, 2021. https://www.amp.org/about/news-room/amp-blog-content/important-issues-to-consider-before-interpreting-and-applying-ct-values-in-clinical-practice/

3. Ct Values: What They Are and How They Can be Used. July 14, 2021, 2021. Accessed July 14, 2021. https://www.aphl.org/programs/preparedness/Crisis-Management/Documents/APHL-COVID19-Ct-Values.pdf

4. AACC Recommendation for Reporting SARS-CoV-2 Cycle Threshold (CT) Values. July 14, 2021. Accessed July 14, 2021. https://www.aacc.org/science-and-research/covid-19-resources/statements-on-covid-19-testing/aacc-recommendation-for-reporting-sars-cov-2-cycle-threshold-ct-values

5. Mandatory Reporting of COVID-19 Laboratory Test Results: Reporting of Cycle Threshold Values. Accessed July 14, 2021. https://www.flhealthsource.gov/files/Laboratory-Reporting-CT-Values-12032020.pdf

6. Rhoads D, Peaper DR, She RC, et al. College of American Pathologists (CAP) Microbiology Committee Perspective: Caution Must Be Used in Interpreting the Cycle Threshold (Ct) Value. Clin Infect Dis. May 18 2021;72(10):e685-e686. doi:10.1093/cid/ciaa1199

7. Hirschhorn JW, Kegl A, Dickerson T, et al. Verification and Validation of SARS-CoV-2 Assay Performance on the Abbott m2000 and Alinity m Systems. J Clin Microbiol. Apr 20 2021;59(5)doi:10.1128/jcm.03119-20

8. Perchetti GA, Pepper G, Shrestha L, et al. Performance characteristics of the Abbott Alinity m SARS-CoV-2 assay. J Clin Virol. Jul 2021;140:104869. doi:10.1016/j.jcv.2021.104869
9. Rodino KG, Espy MJ, Buckwalter SP, et al. Evaluation of Saline, Phosphate-Buffered Saline, and Minimum Essential Medium as Potential Alternatives to Viral Transport Media for SARS-CoV-2 Testing. *J Clin Microbiol*. May 26 2020;58(6) doi:10.1128/jcm.00590-20

10. Rogers AA, Baumann RE, Borillo GA, et al. Evaluation of Transport Media and Specimen Transport Conditions for the Detection of SARS-CoV-2 by Use of Real-Time Reverse Transcription-PCR. *J Clin Microbiol*. Jul 23 2020;58(8) doi:10.1128/jcm.00708-20

11. Perchetti GA, Nalla AK, Huang ML, et al. Validation of SARS-CoV-2 detection across multiple specimen types. *J Clin Virol*. Jul 2020;128:104438. doi:10.1016/j.jcv.2020.104438

12. Callahan C, Lee RA, Lee GR, Zulauf K, Kirby JE, Arnaout R. Nasal Swab Performance by Collection Timing, Procedure, and Method of Transport for Patients with SARS-CoV-2. *J Clin Microbiol*. Jun 2 2021;Jcm0056921. doi:10.1128/jcm.00569-21

13. Griesemer SB, Van Slyke G, Ehrbar D, et al. Evaluation of Specimen Types and Saliva Stabilization Solutions for SARS-CoV-2 Testing. *J Clin Microbiol*. Apr 20 2021;59(5) doi:10.1128/jcm.01418-20

14. Plantamura J, Bousquet A, Otto MP, et al. Performances, feasibility and acceptability of nasopharyngeal swab, saliva and oral-self sampling swab for the detection of severe acute respiratory syndrome coronavirus 2. *Eur J Clin Microbiol Infect Dis*. May 14 2021:1-8. doi:10.1007/s10096-021-04269-4

15. Sharma K, Aggarwala P, Gandhi D, et al. Comparative analysis of various clinical specimens in detection of SARS-CoV-2 using rRT-PCR in new and follow up cases of COVID-19 infection: Quest for the best choice. *PLoS One*. 2021;16(4):e0249408. doi:10.1371/journal.pone.0249408

16. Miranda RL, Guterres A, de Azeredo Lima CH, Filho PN, Gadelha MR. Misinterpretation of viral load in COVID-19 clinical outcomes. *Virus Res*. Apr 15 2021;296:198340. doi:10.1016/j.virusres.2021.198340
17. Baron A, Hachem M, Tran Van Nhieu J, et al. Bronchoalveolar Lavage in Patients with COVID-19 with Invasive Mechanical Ventilation for Acute Respiratory Distress Syndrome. *Ann Am Thorac Soc*. Apr 2021;18(4):723-726. doi:10.1513/AnnalsATS.202007-868RL

18. Zou L, Ruan F, Huang M, et al. SARS-CoV-2 Viral Load in Upper Respiratory Specimens of Infected Patients. *N Engl J Med*. Mar 19 2020;382(12):1177-1179. doi:10.1056/NEJMc2001737

19. Aydillo T, Gonzalez-Reiche AS, Aslam S, et al. Shedding of Viable SARS-CoV-2 after Immunosuppressive Therapy for Cancer. *N Engl J Med*. Dec 24 2020;383(26):2586-2588. doi:10.1056/NEJMc2031670

20. Tarhini H, Recoing A, Bridier-Nahmias A, et al. Long-Term Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) Infectiousness Among Three Immunocompromised Patients: From Prolonged Viral Shedding to SARS-CoV-2 Superinfection. *J Infect Dis*. May 20 2021;223(9):1522-1527. doi:10.1093/infdis/jiab075

21. Taramasso L, Sepulcri C, Mikulska M, et al. Duration of isolation and precautions in immunocompromised patients with COVID-19. *J Hosp Infect*. May 2021;111:202-204. doi:10.1016/j.jhin.2021.02.014

22. Magleby R, Westblade LF, Trzebucki A, et al. Impact of SARS-CoV-2 Viral Load on Risk of Intubation and Mortality Among Hospitalized Patients with Coronavirus Disease 2019. *Clin Infect Dis*. Jun 30 2020;doi:10.1093/cid/ciaa851

23. Zacharioudakis IM, Zervou FN, Prasad PJ, et al. Association of SARS-CoV-2 genomic load trends with clinical status in COVID-19: A retrospective analysis from an academic hospital center in New York City. *PLoS One*. 2020;15(11):e0242399. doi:10.1371/journal.pone.0242399

24. Aydin S, Benk IG, Geckil AA. May viral load detected in saliva in the early stages of infection be a prognostic indicator in COVID-19 patients? *J Virol Methods*. Aug 2021;294:114198. doi:10.1016/j.jviromet.2021.114198
25. Faïco-Filho KS, Passarelli VC, Bellei N. Is Higher Viral Load in SARS-CoV-2 Associated with Death? *Am J Trop Med Hyg.* Nov 2020;103(5):2019-2021. doi:10.4269/ajtmh.20-0954

26. La Scola B, Le Bideau M, Andreani J, et al. Viral RNA load as determined by cell culture as a management tool for discharge of SARS-CoV-2 patients from infectious disease wards. *Eur J Clin Microbiol Infect Dis.* Jun 2020;39(6):1059-1061. doi:10.1007/s10096-020-03913-9

27. Jaafar R, Aherfi S, Wurtz N, et al. Correlation Between 3790 Quantitative Polymerase Chain Reaction-Positives Samples and Positive Cell Cultures, Including 1941 Severe Acute Respiratory Syndrome Coronavirus 2 Isolates. *Clin Infect Dis.* Jun 1 2021;72(11):e921. doi:10.1093/ciaa1491

28. Bullard J, Dust K, Funk D, et al. Predicting Infectious Severe Acute Respiratory Syndrome Coronavirus 2 From Diagnostic Samples. *Clin Infect Dis.* Dec 17 2020;71(10):2663-2666. doi:10.1093/cid/ciaa638

29. Binnicker MJ. Can the Severe Acute Respiratory Syndrome Coronavirus 2 Polymerase Chain Reaction Cycle Threshold Value and Time From Symptom Onset to Testing Predict Infectivity? *Clin Infect Dis.* Dec 17 2020;71(10):2667-2668. doi:10.1093/cid/ciaa735

30. Basile K, McPhie K, Carter I, et al. Cell-based culture of SARS-CoV-2 informs infectivity and safe de-isolation assessments during COVID-19. *Clin Infect Dis.* Oct 24 2020;doi:10.1093/ciaa1579

31. van Kampen JJA, van de Vijver D, Fraaij PLA, et al. Duration and key determinants of infectious virus shedding in hospitalized patients with coronavirus disease-2019 (COVID-19). *Nat Commun.* Jan 11 2021;12(1):267. doi:10.1038/s41467-020-20568-4

32. Biosafety for Specimen Handling. Accessed July 14, 2021. https://www.cdc.gov/coronavirus/2019-ncov/lab/lab-biosafety-guidelines.html

33. Laboratory biosafety guidance related to coronavirus disease (COVID-19): Interim guidance, 28 January 2021. Accessed July 14, 2021. https://www.who.int/publications/i/item/WHO-WPE-GIH-2021.1
34. Tian D, Lin Z, Kriner EM, et al. Ct Values Do not Predict SARS-CoV-2 Transmissibility in College Students. *J Mol Diagn.* Jun 5 2021;doi:10.1016/j.jmoldx.2021.05.012

35. Lee LYW, Rozmanowski S, Pang M, et al. SARS-CoV-2 infectivity by viral load, S gene variants and demographic factors and the utility of lateral flow devices to prevent transmission. *Clin Infect Dis.* May 11 2021;doi:10.1093/cid/ciab421

36. Marks M, Millat-Martinez P, Ouchi D, et al. Transmission of COVID-19 in 282 clusters in Catalonia, Spain: a cohort study. *Lancet Infect Dis.* May 2021;21(5):629-636. doi:10.1016/s1473-3099(20)30985-3